Intenzivní léčba závislosti na tabáku v Česku v letech 2010–2022
Authors:
Kamila Zvolská 1; Miroslav Zvolský 2; Jolana Čady 2; Eva Králíková 1,3
Authors place of work:
Centrum pro závislé na tabáku, 3. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze
1; Ústav zdravotnických informací a statistiky ČR
2; Ústav hygieny a epidemiologie 1. LF UK a VFN v Praze
3
Published in the journal:
Čas. Lék. čes. 2024; 163: 44-48
Category:
Original Article
Summary
In the 10th version of the World Health Organization’s International Classification of Diseases, tobacco dependence is a separate diagnostic unit, F17. As with other diseases, there are effective treatments – psychobehavioral interventions and pharmacotherapy to suppress withdrawal symptoms. The aim of this analysis was to evaluate the development of reporting of selected intensive tobacco dependence treatment interventions in the Czech Republic.
Data provided by the National Register of Covered Health Services of the Institute of Health Information and Statistics of the Czech Republic for the period 2010–2022, with a distinction per county and anonymized per centers for tobacco dependence and trained physicians.
Between 2010 and 2022, an average of 1094 initial intervention procedures were reported annually in the country, indicating the number of smokers treated, and 2584 control visits. The Centre for Tobacco Dependence of the General University Hospital in Prague had the largest share in the total reporting of 25501 procedures (average 35.5 %).
Intensive treatment for tobacco dependence should be offered and available as treatment for other diseases. However, of the approximately two million smokers in the Czech Republic, only about 0.5 ‰ undergo it annually.
Keywords:
tobacco dependence, treatment, reporting, health performance
Zdroje
- WHO report on the global tobacco epidemic, 2023: protect people from tobacco smoke. WHO, 2023. Dostupné na: www.who.int/publications/i/item/9789240077164
- Csémy L, Dvořáková Z, Fialová A a kol. Národní výzkum užívání tabáku a alkoholu v České republice 2022 (NAUTA). SZÚ, Praha, 2023.
- Peto R, Lopez AD, Hongchao P et al. Mortality from smoking in developed countries 1950–2020. CTSU, 2015. Dostupné na: https://gas.ctsu.ox.ac.uk/tobacco
- GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 2017; 389: 1885–1906.
- American Psychiatric Association, DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). APA, 2023.
- Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2008; 75: 178–195.
- Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res 2012; 14: 75–78.
- Zvolská K, Štěpánková L, Pánková A, Králíková E. Minnesotská škála tabákových abstinenčních příznaků, revize 2020, validizované české znění. Čas Lék Čes 2023; 162: 104–105.
- West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299–303.
- Fiore MC, Jaén CR, Baker TB et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. US Department of Health and Human Services, Rockville, 2008.
- Králíková E, Aschermann M, Dvořák V a kol. Léčba závislosti na tabáku. Klinický doporučený postup. ÚZIS ČR, 2022.
- Šťastný B, Králíková E, Seifert B a kol. Léčba závislosti na tabáku v ordinaci všeobecného praktického lékaře. Doporučené diagnostické a léčebné postupy pro všeobecné praktické lékaře. SVL ČLS JEP, Praha, 2022.
- Králíková E, Zvolská K, Štěpánková L a kol. Doporučení pro léčbu závislosti na tabáku. Čas Lék Čes 2022; 161: 33–43.
- Kde hledat pomoc. Společnost pro léčbu závislosti na tabáku, 2024. Dostupné na: www.slzt.cz/centra/centra-pro-zavisle-na-tabaku#more-informations
- Thomas KH, Dalili MN, López-López JA et al. Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess 2021; 25: 1–224.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Metamizole vs. Tramadol in Postoperative Analgesia
- Spasmolytic Effect of Metamizole
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
Najčítanejšie v tomto čísle
- Akatizie – častý, ale obtížně rozpoznatelný nežádoucí účinek?
- Polypragmazie a jak jí předcházet
- Geografie zdraví – průzkum prostorových nerovností ve zdraví v Česku
- Lékové interakce – rizika u pacientů s polypragmazií